Neuland Laboratories has announced strategic modifications to its executive leadership roles, effective April 1, 2026, to support organizational growth. Mr. Sucheth Rao Davuluri will become Executive Vice Chairman, focusing on long-term strategy. Mr. Saharsh Rao Davuluri will assume the role of CEO & Managing Director, overseeing daily operations and leveraging his CDMO expertise. This transition aims to ensure a balanced focus on both short-term and long-term objectives.
Executive Leadership Transition
Neuland Laboratories has announced changes to the responsibilities of its executive leadership, set to take effect on April 1, 2026. This decision, made by the Board of Directors, is intended to support the company’s growth plans and to maintain focus on both short-term performance and long-term strategic goals.
Sucheth Rao Davuluri’s New Role
Mr. Sucheth Rao Davuluri, currently Vice Chairman & CEO, will be re-designated as Executive Vice Chairman. In this new role, he will concentrate on strategic areas such as long-term planning, enterprise risk management, stakeholder management, internal audit oversight, and corporate social responsibility (CSR) initiatives through the Neuland Foundation. His previous work has significantly contributed to Neuland’s evolution into a quality-focused API company diversifying into specialty APIs and CDMO services.
Saharsh Rao Davuluri Appointed CEO & Managing Director
Mr. Saharsh Rao Davuluri, currently Vice Chairman & Managing Director, will take on the role of CEO & Managing Director. He will be responsible for day-to-day operations, leveraging his experience in building the CMS business to better meet client needs and maintain customer trust and goodwill. His prior contributions have been pivotal in establishing Neuland’s reputation as a leading CDMO.
Transition Period
A transition period will commence immediately and continue until March 31, 2026, to ensure a smooth transfer of operational responsibilities. The new roles and responsibilities will be formally implemented on April 1, 2026, subject to shareholder approval. Both Mr. Sucheth Davuluri and Mr. Saharsh Davuluri will continue to report directly to the Executive Chairman, Dr. D. R. Rao.
Source: BSE
